Expanded Access (Compassionate Use) Policy

Kubota Vision is committed to developing promising new therapies to address the unmet medical needs of patients suffering from debilitating ocular diseases. We currently have a late-stage investigational medicine (emixustat) in our product pipeline for the treatment of Stargardt disease. Our goal is to provide access to emiuxstat at the appropriate time and in a manner that is most beneficial to the relevant patient population. We believe enrollment in our clinical trials is the safest and most effective way of achieving this goal. We do recognize that some patients will not be eligible for our clinical trials and may wish to access our products through expanded access programs. At this time, we have announced an expanded access program in France, which will begin later in 2026. We are also actively working to offer expanded access programs in other countries around the world.

Kubota Vision may revise this expanded access policy at any time. Additionally, the posting of this policy by Kubota Vision does not serve as a guarantee of access to any specific investigational new drug by any individual patient. You can find further contact details on the Contact Us page of our website.